We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+6.25%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$17.4B
AUM Growth
+$904M
Cap. Flow
+$84.9M
Cap. Flow %
0.49%
Top 10 Hldgs %
29.78%
Holding
722
New
36
Increased
329
Reduced
218
Closed
40

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$66.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$57.7M
3
AMZN icon
Amazon
AMZN
+$56.5M
4
AMD icon
Advanced Micro Devices
AMD
+$37.5M
5
CRM icon
Salesforce
CRM
+$35.5M

Top Sells

Rank Stock Value
1
LRCX icon
Lam Research
LRCX
+$122M
2
TMO icon
Thermo Fisher Scientific
TMO
+$60.8M
3
AMAT icon
Applied Materials
AMAT
+$43.7M
4
NU icon
Nu Holdings
NU
+$35.9M
5
INCY icon
Incyte
INCY
+$32.5M

Sector Composition

Rank Sector Weight
1 Technology 31.8%
2 Healthcare 28.54%
3 Financials 9.44%
4 Consumer Discretionary 7.84%
5 Industrials 7.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYTM icon
176
Rhythm Pharmaceuticals
RYTM
$7.28B
$20.7M 0.12%
395,377
+123,979
+46% +$5.94M
ACLX
177
DELISTED
Arcellx
ACLX
$20.1M 0.12%
240,363
+23,355
+11% +$1.56M
KROS icon
178
Keros Therapeutics
KROS
$202M
$20.1M 0.12%
345,384
-96,471
-22% -$4.76M
JXN icon
179
Jackson Financial
JXN
$8.44B
$20M 0.11%
219,097
-13,449
-6% -$1.12M
VERA icon
180
Vera Therapeutics
VERA
$2.53B
$19.9M 0.11%
450,992
+157,232
+54% +$5.97M
MIRM icon
181
Mirum Pharmaceuticals
MIRM
$6.96B
$19.8M 0.11%
508,475
– –
APLS
182
DELISTED
Apellis Pharmaceuticals
APLS
$19.6M 0.11%
680,058
+137,023
+25% +$5.07M
MCO icon
183
Moody's
MCO
$84.2B
$19.3M 0.11%
40,711
+1,695
+4% +$786K
SNDX icon
184
Syndax Pharmaceuticals
SNDX
$1.82B
$19.2M 0.11%
998,619
+28,513
+3% +$589K
URI icon
185
United Rentals
URI
$70.2B
$19.1M 0.11%
23,553
-2,037
-8% -$1.47M
AZO icon
186
AutoZone
AZO
$50.2B
$19M 0.11%
6,031
+20
+0.3% +$61.4K
UPS icon
187
United Parcel Service
UPS
$96B
$19M 0.11%
139,154
+73,792
+113% +$9.69M
CLH icon
188
Clean Harbors
CLH
$15.9B
$18.9M 0.11%
78,353
-14,906
-16% -$3.5M
MTZ icon
189
MasTec
MTZ
$26.6B
$18.7M 0.11%
152,109
-901
-0.6% -$98.4K
SMMT icon
190
Summit Therapeutics
SMMT
$10.5B
$18.6M 0.11%
+850,403
New +$11.9M
XENE icon
191
Xenon Pharmaceuticals
XENE
$6.36B
$18.3M 0.1%
463,861
-57,975
-11% -$2.34M
CM icon
192
Canadian Imperial Bank of Commerce
CM
$108B
$18.2M 0.1%
296,702
-104,046
-26% -$5.63M
ORCL icon
193
Oracle
ORCL
$345B
$18.2M 0.1%
106,576
+3,462
+3% +$501K
ILMN icon
194
Illumina
ILMN
$28.7B
$18M 0.1%
138,270
-66,773
-33% -$8.24M
OLMA icon
195
Olema Pharmaceuticals
OLMA
$1.05B
$18M 0.1%
1,506,764
+448,091
+42% +$5.73M
LEGN icon
196
Legend Biotech
LEGN
$3.73B
$17.8M 0.1%
365,987
+104,952
+40% +$5.59M
KURA icon
197
Kura Oncology
KURA
$901M
$17.7M 0.1%
906,482
– –
GDDY icon
198
GoDaddy
GDDY
$12.8B
$17.6M 0.1%
112,430
+96,813
+620% +$14.8M
TGT icon
199
Target
TGT
$63.7B
$17.6M 0.1%
112,884
+16,952
+18% +$2.52M
DOV icon
200
Dover
DOV
$27.7B
$17.5M 0.1%
91,488
-369
-0.4% -$67.2K
6 7
8
9 10

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q3 2024 Portfolio in Review

As of Q3 2024, Candriam SCA held 722 positions worth $17.4B, up 5.5% from $16.5B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Candriam SCA's Q3 2024 filing shows 36 new, 329 increased, 218 reduced and 40 closed positions. Its largest new stake was Avidity Biosciences: 323,396 shares worth $14.9M. The largest sale was Lam Research, an estimated $122M.

By sector, the portfolio is most concentrated in Technology at 32% of assets, down from 33% a quarter earlier, followed by Healthcare and Financials.

  • Candriam SCA's largest Q3 2024 buy was Avidity Biosciences: 323,396 shares worth $14.9M.
  • Candriam SCA added most to Amgen in Q3 2024, an estimated $66.4M increase.
  • Candriam SCA's biggest Q3 2024 reduction was Thermo Fisher Scientific, cutting an estimated $60.8M.
  • Candriam SCA fully exited Lam Research in Q3 2024, selling an estimated $122M.
  • Candriam SCA's ten largest holdings make up 30% of its $17.4B portfolio in Q3 2024.
  • Candriam SCA opened 36 new positions and closed 40 in Q3 2024.
  • Candriam SCA's portfolio value rose 5.5% quarter-over-quarter to $17.4B.

Based on Candriam SCA's 13F filing for Q3 2024, filed 13 Nov 2024.